Target Validation Information
Target ID T35734
Target Name Soluble epoxide hydrolase
Target Type
Clinical Trial
Drug Potency against Target 1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea Drug Info IC50 = 3.5 nM [531143]
1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea Drug Info IC50 = 10 nM [528339]
1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea Drug Info IC50 = 3800 nM [528339]
6-amino-N-(2,4-dichlorobenzyl)nicotinamide Drug Info IC50 = 430 nM [530386]
1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea Drug Info IC50 = 39 nM [530204]
1-(3-Chloro-phenyl)-3-cyclohexyl-urea Drug Info IC50 = 190 nM [527552]
N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide Drug Info IC50 = 2100 nM [527552]
1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea Drug Info IC50 = 810 nM [528339]
1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea Drug Info IC50 = 0.9 nM [531143]
Trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea Drug Info IC50 = 1400 nM [528938]
16-(3-Ethylureido)hexadec-11(Z)-enoic acid Drug Info IC50 = 2596 nM [530294]
1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea Drug Info IC50 = 1200 nM [528339]
1-Octyl-3-(1-propionylpiperidin-4-yl)urea Drug Info IC50 = 0.4 nM [531143]
1-Adamantan-1-yl-3-decyl-urea Drug Info IC50 = 110 nM [527552]
N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine Drug Info IC50 = 960 nM [530329]
N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine Drug Info IC50 = 740 nM [530329]
1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea Drug Info IC50 = 3.9 nM [528938]
Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea Drug Info IC50 = 76 nM [528938]
N,N'-dicyclohexyl-urea Drug Info IC50 = 52 nM [528938]
Cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea Drug Info IC50 = 4 nM [528938]
N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea Drug Info IC50 = 6 nM [528938]
1-Cyclohexyl-3-(4-methoxy-phenyl)-urea Drug Info IC50 = 230 nM [527552]
1-Cyclohexyl-3-phenethyl-urea Drug Info IC50 = 160 nM [527552]
1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea Drug Info IC50 = 14 nM [529961]
2-Cyclohexyl-N-phenethyl-acetamide Drug Info IC50 = 4000 nM [527552]
2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide Drug Info IC50 = 6200 nM [527552]
N-Cyclohexyl-2-phenyl-acetamide Drug Info IC50 = 14000 nM [527552]
N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide Drug Info IC50 = 50 nM [530386]
1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea Drug Info IC50 = 130 nM [527552]
13-n-Heptanamidotridec-8(Z)-enoic acid Drug Info IC50 = 79 nM [530294]
1-Cyclohexyl-3-phenyl-urea Drug Info IC50 = 1390 nM [527552]
N-(4,4-Diphenyl-butyl)-nicotinamide Drug Info IC50 = 26 nM [530375]
14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid Drug Info IC50 = 66 nM [530294]
1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea Drug Info IC50 = 3100 nM [527552]
9-(3-n-Pentylureido)non-4-ynoic acid Drug Info IC50 = 8110 nM [530294]
Dodecanoic acid adamantan-1-ylamide Drug Info IC50 = 5000 nM [527552]
N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide Drug Info IC50 = 150 nM [530375]
1-adamantan-1-yl-3-(4-hydroxybutyl)urea Drug Info IC50 = 531 nM [529063]
1-adamantan-1-yl-3-(3-hexyloxypropyl)urea Drug Info IC50 = 5.6 nM [529063]
1-adamantan-1-yl-3-(5-butoxypentyl)urea Drug Info IC50 = 4.1 nM [529063]
1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea Drug Info IC50 = 8544 nM [529961]
12-(3-n-Hexylureido)dodec-8(Z)-enoic acid Drug Info IC50 = 16 nM [530294]
13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid Drug Info IC50 = 3480 nM [530294]
1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea Drug Info IC50 = 139 nM [529961]
1-adamantan-1-yl-3-(6-propyloxyhexyl)urea Drug Info IC50 = 3.7 nM [529063]
N-(3-Phenyl-propyl)-nicotinamide Drug Info IC50 = 70 nM [530375]
N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine Drug Info IC50 = 4600 nM [530329]
1-Phenyl-3-(1-propionylpiperidin-4-yl)urea Drug Info IC50 = 49 nM [531143]
1-adamantan-1-yl-3-(4-pentyloxybutyl)urea Drug Info IC50 = 4.4 nM [529063]
1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea Drug Info IC50 = 1.2 nM [529063]
1-adamantan-1-yl-3-(6-hydroxyhexyl)urea Drug Info IC50 = 12 nM [529063]
1-Adamantan-1-yl-3-phenyl-urea Drug Info IC50 = 17 nM [529961]
1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea Drug Info IC50 = 24 nM [529961]
N-Cyclohexyl-4-phenyl-butyramide Drug Info IC50 = 1400 nM [527552]
12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid Drug Info IC50 = 1374 nM [530294]
1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea Drug Info IC50 = 28 nM [529961]
[4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid Drug Info IC50 = 392 nM [529961]
1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea Drug Info IC50 = 8.7 nM [531143]
2-Adamantan-1-yl-N-decyl-acetamide Drug Info IC50 = 100 nM [527552]
2-Cyclohexyl-N-phenyl-acetamide Drug Info IC50 = 16000 nM [527552]
13-(3-n-Pentylureido)tridec-8-ynoic acid Drug Info IC50 = 43 nM [530294]
1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea Drug Info IC50 = 55 nM [531143]
1-adamantan-1-yl-3-piperidin-4-yl-urea Drug Info IC50 = 300 nM [528339]
N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide Drug Info IC50 = 4800 nM [527552]
13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid Drug Info IC50 = 7147 nM [530294]
N-(3,3-Diphenyl-propyl)-isonicotinamide Drug Info IC50 = 7.6 nM [530375]
1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea Drug Info IC50 = 1.2 nM [531143]
1-adamantan-1-yl-3-(5-hydroxypentyl)urea Drug Info IC50 = 84 nM [529063]
13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid Drug Info IC50 = 10712 nM [530294]
9-(3-n-Pentylureido)non-4(Z)-enoic acid Drug Info IC50 = 1355 nM [530294]
13-(3-n-Pentylureido)tridec-5(Z)-enoic acid Drug Info IC50 = 793 nM [530294]
13-(3-n-Pentylureido)tridec-8(E)-enoic acid Drug Info IC50 = 48.5 nM [530294]
6-amino-N-(3,3-diphenylpropyl)nicotinamide Drug Info IC50 = 8.5 nM [530386]
4,4-Diphenyl-N-(pyridin-3-yl)-butyramide Drug Info IC50 = 18 nM [530375]
13-(3-Pentyluredo)tridec-8(Z)-enoic acid Drug Info IC50 = 46 nM [530294]
13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid Drug Info IC50 = 770 nM [530294]
N-adamantyl-N'-cyclohexylurea Drug Info IC50 = 1.6 nM [528938]
1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea Drug Info IC50 = 38 nM [530204]
1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea Drug Info IC50 = 1700 nM [531143]
1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea Drug Info IC50 = 100 nM [528417]
13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid Drug Info IC50 = 11194 nM [530294]
Methyl 4-(3-cyclohexylureido)butanoate Drug Info IC50 = 330 nM [528366]
1-adamantan-1-yl-3-(3-hydroxypropyl)urea Drug Info IC50 = 746 nM [529063]
1-adamantan-1-yl-3-(2-heptyloxyethyl)urea Drug Info IC50 = 29 nM [529063]
N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine Drug Info IC50 = 1200 nM [530329]
1-adamantan-1-yl-3-(2-hydroxyethyl)urea Drug Info IC50 = 482 nM [529063]
4-(3-cyclohexylureido)butanoic acid Drug Info IC50 = 1900 nM [528366]
Methyl 6-(3-cyclohexylureido)hexanoate Drug Info IC50 = 110 nM [528366]
N-(3,3-diphenyl-propyl)-nicotinamide Drug Info IC50 = 4.8 nM [530375]
13-n-Heptanamidotridec-5-ynoic acid Drug Info IC50 = 272 nM [530294]
12-(3-Adamantan-1-yl-ureido)-dodeca noic acid Drug Info IC50 = 5 nM [530286]
N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide Drug Info IC50 = 7 nM [530375]
N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide Drug Info IC50 = 7.2 nM [530375]
1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea Drug Info IC50 = 4.7 nM [529961]
4-(3-Adamantan-1-yl-ureido)-benzoic acid Drug Info IC50 = 1411 nM [529961]
3-(3-Adamantan-1-yl-ureido)-benzoic acid Drug Info IC50 = 365 nM [529961]
Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate Drug Info IC50 = 152 nM [530294]
1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea Drug Info IC50 = 4200 nM [528339]
References
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 528339Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. Epub 2006 Jul 25.Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Ref 528339Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. Epub 2006 Jul 25.Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Ref 530386Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. Epub 2009 Aug 26.Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
Ref 530204Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63. Epub 2009 May 30.Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 528339Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. Epub 2006 Jul 25.Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 528938J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 528339Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. Epub 2006 Jul 25.Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530329Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. Epub 2009 Aug 7.A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
Ref 530329Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. Epub 2009 Aug 7.A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
Ref 528938J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Ref 528938J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Ref 528938J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Ref 528938J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Ref 528938J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530386Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. Epub 2009 Aug 26.Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 530329Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. Epub 2009 Aug 7.A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 528339Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. Epub 2006 Jul 25.Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Ref 527552J Med Chem. 2005 May 19;48(10):3621-9.Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530386Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. Epub 2009 Aug 26.Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 528938J Med Chem. 2007 Aug 9;50(16):3825-40. Epub 2007 Jul 6.Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Ref 530204Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63. Epub 2009 May 30.Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase.
Ref 531143J Med Chem. 2010 Oct 14;53(19):7067-75.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Ref 528417Bioorg Med Chem Lett. 2006 Nov 15;16(22):5773-7. Epub 2006 Sep 1.Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 528366Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44.Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 530329Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. Epub 2009 Aug 7.A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
Ref 529063J Med Chem. 2007 Oct 18;50(21):5217-26. Epub 2007 Sep 26.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokineticproperties.
Ref 528366Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44.Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
Ref 528366Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44.Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 530286J Med Chem. 2009 Aug 27;52(16):5009-12.Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 530375J Med Chem. 2009 Oct 8;52(19):5880-95.Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 529961Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. Epub 2009 Jan 27.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.
Ref 530294J Med Chem. 2009 Aug 27;52(16):5069-75.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.
Ref 528339Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. Epub 2006 Jul 25.Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.